CIALIS®
(tadalafil)
tables

DESCRIPTION

CIALIS® (tadalafil), an oral treatment for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Tadalafil has the empirical formula C_{22}H_{19}N_{5}O_{4} representing a molecular weight of 389.41. The structural formula is:

![Tadalafil Structural Formula]

The chemical designation is pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-6(R,12aR)-. It is a crystalline solid that is practically insoluble in water and very slightly soluble in ethanol.

CIALIS is available as film-coated, almond-shaped tablets for oral administration. Each tablet contains 5, 10, or 20 mg of tadalafil and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.

CLINICAL PHARMACOLOGY

Mechanism of Action

Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the amount of cGMP. Tadalafil inhibits PDE5. Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 by tadalafil has no effect in the absence of sexual stimulation.

Studies in vitro have demonstrated that tadalafil is a selective inhibitor of PDE5. PDE5 is found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung, cerebellum, and pancreas.

In vitro studies have shown that the effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. These studies have shown that tadalafil is >10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4, and PDE7 enzymes, which are found in the heart, brain, blood vessels, liver, leukocytes, skeletal muscle, and other organs. Tadalafil is >10,000-fold more potent for PDE5
than for PDE3, an enzyme found in the heart and blood vessels. Additionally, tadalafil is 700-fold more potent for PDE5 than for PDE6, which is found in the retina and is responsible for phototransduction. Tadalafil is $>9,000$-fold more potent for PDE5 than for PDE8, PDE9, and PDE10 and 14-fold more potent for PDE5 than for PDE11A1, an enzyme found in human skeletal muscle. Tadalafil inhibits human recombinant PDE11A1 activity at concentrations within the therapeutic range. The physiological role and clinical consequence of PDE11 inhibition in humans have not been defined.

**Pharmacokinetics**

Over a dose range of 2.5 to 20 mg, tadalafil exposure (AUC) increases proportionally with dose in healthy subjects. Steady-state plasma concentrations are attained within 5 days of once-daily dosing, and exposure is approximately 1.6-fold greater than after a single dose. Tadalafil is eliminated predominantly by hepatic metabolism, mainly by cytochrome P450 3A4 (CYP3A4). The concomitant use of potent CYP3A4 inhibitors such as ritonavir or ketoconazole resulted in significant increases in tadalafil AUC values (*see PRECAUTIONS and DOSAGE AND ADMINISTRATION*). Mean tadalafil concentrations measured after the administration of a single oral dose of 20 mg to healthy male subjects are depicted in Figure 1.

![Graph showing plasma tadalafil concentrations over time](image)

**Figure 1:** Plasma tadalafil concentrations (mean ± SD) following a single 20-mg tadalafil dose

*Absorption* — After single oral-dose administration, the maximum observed plasma concentration ($C_{\text{max}}$) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.

The rate and extent of absorption of tadalafil are not influenced by food; thus CIALIS may be taken with or without food.
Distribution — The mean apparent volume of distribution following oral administration is approximately 63 L, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins.

Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.

Metabolism — Tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite. The catechol metabolite undergoes extensive methylation and glucuronidation to form the methylcatechol and methylcatechol glucuronide conjugate, respectively. The major circulating metabolite is the methylcatechol glucuronide. Methylcatechol concentrations are less than 10% of glucuronide concentrations. In vitro data suggests that metabolites are not expected to be pharmacologically active at observed metabolite concentrations.

Elimination — The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 17.5 hours in healthy subjects. Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).

Pharmacokinetics in Special Populations

Geriatric — Healthy male elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) with no effect on Cmax relative to that observed in healthy subjects 19 to 45 years of age. No dose adjustment is warranted based on age alone. However, greater sensitivity to medications in some older individuals should be considered (see Geriatric Use under PRECAUTIONS).

Pediatric — Tadalafil has not been evaluated in individuals less than 18 years old.

Hepatic Impairment — In clinical pharmacology studies, tadalafil exposure (AUC) in subjects with mild or moderate hepatic impairment (Child-Pugh Class A or B) was comparable to exposure in healthy subjects when a dose of 10 mg was administered. There are no available data for doses higher than 10 mg of tadalafil in patients with hepatic impairment. Insufficient data are available for subjects with severe hepatic impairment (Child-Pugh Class C). Therefore, for patients with mild or moderate hepatic impairment, the maximum dose should not exceed 10 mg, and use in patients with severe hepatic impairment is not recommended (see DOSAGE AND ADMINISTRATION).

Renal Insufficiency — In clinical pharmacology studies using single-dose tadalafil (5 to 10 mg), tadalafil exposure (AUC) doubled in subjects with mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min) renal insufficiency. In subjects with end-stage renal disease on hemodialysis, there was a two-fold increase in Cmax and 2.7- to 4.1-fold increase in AUC following single-dose administration of 10 or 20 mg tadalafil. Exposure to total methylcatechol (unconjugated plus glucuronide) was 2- to 4-fold higher in subjects with renal impairment, compared to those with normal renal function. Hemodialysis (performed between 24 and 30 hours post-dose) contributed negligibly to tadalafil or metabolite elimination. In a clinical pharmacology study (N=28) at a dose of 10 mg, back pain was reported as a limiting adverse event in male patients with moderate renal impairment. At a dose of 5 mg, the incidence and severity of back pain was not significantly different than in the general population. In patients on hemodialysis taking 10- or 20-mg tadalafil, there were no reported cases of back pain. The dose of tadalafil should be limited to 5 mg not more than once daily in patients with severe renal insufficiency or end-stage renal disease. A starting dose of 5 mg not more than once daily is recommended for patients with moderate renal insufficiency; the maximum recommended dose is 10 mg not more than once in every 48 hours. No dose adjustment is required in patients with mild renal insufficiency (see DOSAGE AND ADMINISTRATION).
Patients with Diabetes Mellitus — In male patients with diabetes mellitus after a 10 mg tadalafil dose, exposure (AUC) was reduced approximately 19% and $C_{\text{max}}$ was 5% lower than that observed in healthy subjects. No dose adjustment is warranted.

Pharmacodynamics

Effects on Blood Pressure — Tadalafil 20 mg administered to healthy male subjects produced no significant difference compared to placebo in supine systolic and diastolic blood pressure (difference in the mean maximal decrease of 1.6/0.8 mm Hg, respectively) and in standing systolic and diastolic blood pressure (difference in the mean maximal decrease of 0.2/4.6 mm Hg, respectively). In addition, there was no significant effect on heart rate.

Effects on Blood Pressure when CIALIS is Administered with Nitrates — In clinical pharmacology studies, tadalafil (5 to 20 mg) was shown to potentiate the hypotensive effect of nitrates. Therefore, the use of CIALIS in patients taking any form of nitrates is contraindicated (see CONTRAINDICATIONS).

A study was conducted to assess the degree of interaction between nitroglycerin and tadalafil, should nitroglycerin be required in an emergency situation after tadalafil was taken. This was a double-blind, placebo-controlled, crossover study in 150 male subjects at least 40 years of age (including subjects with diabetes mellitus and/or controlled hypertension) and receiving daily doses of tadalafil 20 mg or matching placebo for 7 days. Subjects were administered a single dose of 0.4 mg sublingual nitroglycerin (NTG) at pre-specified timepoints, following their last dose of tadalafil (2, 4, 8, 24, 48, 72, and 96 hours after tadalafil). The objective of the study was to determine when, after tadalafil dosing, no apparent blood pressure interaction was observed. In this study, a significant interaction between tadalafil and NTG was observed at each timepoint up to and including 24 hours. At 48 hours, by most hemodynamic measures, the interaction between tadalafil and NTG was not observed, although a few more tadalafil subjects compared to placebo experienced greater blood-pressure lowering at this timepoint. After 48 hours, the interaction was not detectable (see Figure 2).
Figure 2: Mean Maximal Change in Blood Pressure (Tadalafil Minus Placebo, Point Estimate with 90% CI) in Response to Sublingual Nitroglycerin at 2 (Supine Only), 4, 8, 24, 48, 72, and 96 Hours after the Last Dose of Tadalafil 20 mg or Placebo

Therefore, CIALIS administration with nitrates is contraindicated. In a patient who has taken CIALIS, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of CIALIS before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring (see CONTRAINDICATIONS).

Effects on Exercise Stress Testing — The effects of tadalafil on cardiac function, hemodynamics, and exercise tolerance were investigated in a single clinical pharmacology study. In this blinded crossover trial, 23 subjects with stable coronary artery disease and evidence of exercise-induced cardiac ischemia were enrolled. The primary endpoint was time to cardiac ischemia. The mean difference in total exercise time was 3 seconds (tadalafil 10 mg minus placebo), which represented no clinically meaningful difference. Further statistical analysis demonstrated that tadalafil was non-inferior to placebo with respect to time to ischemia. Of note, in this study, in some subjects who received tadalafil followed by sublingual nitroglycerin in the post-exercise period, clinically significant reductions in blood pressure were observed, consistent with the augmentation by tadalafil of the blood-pressure-lowering effects of nitrates.

Effects on Vision — Single oral doses of phosphodiesterase inhibitors have demonstrated transient dose-related impairment of color discrimination (blue/green), using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. In a study to assess the effects of a single dose of tadalafil 40 mg on vision (N=59), no effects were observed on visual acuity, intraocular
pressure, or pupillometry. Across all clinical studies with CIALIS, reports of changes in color vision were rare (<0.1% of patients).

Effects on Sperm Characteristics — There were no clinically relevant effects on sperm concentration, sperm count, motility, or morphology in humans in placebo-controlled studies of daily doses of tadalafil 10 mg (N=204) or 20 mg (N=217) for 6 months. In addition, tadalafil had no effect on serum levels of testosterone, luteinizing hormone, or follicle stimulating hormone.

Effects on Cardiac Electrophysiology — The effect of a single 100-mg dose of tadalafil on the QT interval was evaluated at the time of peak tadalafil concentration in a randomized, double-blinded, placebo, and active (intravenous ibutilide)-controlled crossover study in 90 healthy males aged 18 to 53 years. The mean change in QTc (Fridericia QT correction) for tadalafil, relative to placebo, was 3.5 milliseconds (two-sided 90% CI=1.9, 5.1). The mean change in QTc (Individual QT correction) for tadalafil, relative to placebo, was 2.8 milliseconds (two-sided 90% CI=1.2, 4.4). A 100-mg dose of tadalafil (5 times the highest recommended dose) was chosen because this dose yields exposures covering those observed upon coadministration of tadalafil with potent CYP3A4 inhibitors or those observed in renal impairment. In this study, the mean increase in heart rate associated with a 100-mg dose of tadalafil compared to placebo was 3.1 beats per minute.

Clinical Studies
The efficacy and safety of tadalafil in the treatment of erectile dysfunction has been evaluated in 22 clinical trials of up to 24-weeks duration, involving over 4000 patients. CIALIS, when taken as needed up to once daily, was shown to be effective in improving erectile function in men with erectile dysfunction (ED).

Study Design — CIALIS was studied in the general ED population in 7 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12-weeks duration. Two of these studies were conducted in the United States and 5 were conducted in centers outside the US. Additional efficacy and safety studies were performed in ED patients with diabetes mellitus and in patients who developed ED status post bilateral nerve-sparing radical prostatectomy.

In these 7 trials, CIALIS was taken as needed, at doses ranging from 2.5 to 20 mg, up to once daily. Patients were free to choose the time interval between dose administration and the time of sexual attempts. Food and alcohol intake were not restricted.

Several assessment tools were used to evaluate the effect of CIALIS on erectile function. The 3 primary outcome measures were the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) and Questions 2 and 3 from Sexual Encounter Profile (SEP). The IIEF is a 4-week recall questionnaire that was administered at the end of a treatment-free baseline period and subsequently at follow-up visits after randomization. The IIEF EF domain has a 30-point total score, where higher scores reflect better erectile function. SEP is a diary in which patients recorded each sexual attempt made throughout the study. SEP Question 2 asks, “Were you able to insert your penis into your partner’s vagina?” SEP Question 3 asks, “Did your erection last long enough for you to have successful intercourse?” The overall percentage of successful attempts to insert the penis into the vagina (SEP2) and to maintain the erection for successful intercourse (SEP3) is derived for each patient.

Study Results —

ED Population in US Trials — The 2 primary US efficacy and safety trials included a total of 402 men with erectile dysfunction, with a mean age of 59 years (range 27 to 87 years). The population was 78% White, 14% Black, 7% Hispanic, and 1% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease. Most (>90%) patients reported ED of at least 1-year duration. Study A was conducted primarily in academic centers.
Study B was conducted primarily in community-based urology practices. In each of these 2 trials, CIALIS 20 mg showed clinically meaningful and statistically significant improvements in all 3 primary efficacy variables (see Table 1). The treatment effect of CIALIS did not diminish over time.

Table 1: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Primary US Trials

<table>
<thead>
<tr>
<th></th>
<th>Study A</th>
<th></th>
<th>Study B</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>CIALIS 20 mg</td>
<td>Placebo</td>
<td>CIALIS 20 mg</td>
</tr>
<tr>
<td></td>
<td>(N=49)</td>
<td>(N=146) p-value</td>
<td>(N=48)</td>
<td>(N=159) p-value</td>
</tr>
<tr>
<td><strong>EF Domain Score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint</td>
<td>13.5</td>
<td>19.5</td>
<td>13.6</td>
<td>22.5</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>-0.2</td>
<td>6.9</td>
<td>&lt;.001</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Insertion of Penis (SEP2)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint</td>
<td>39%</td>
<td>62%</td>
<td>43%</td>
<td>77%</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>2%</td>
<td>26%</td>
<td>&lt;.001</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Maintenance of Erection (SEP3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint</td>
<td>25%</td>
<td>50%</td>
<td>23%</td>
<td>64%</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>5%</td>
<td>34%</td>
<td>&lt;.001</td>
<td>4%</td>
</tr>
</tbody>
</table>

General ED Population in Trials Outside the US — The 5 primary efficacy and safety studies conducted in the general ED population outside the US included 1112 patients, with a mean age of 59 years (range 21 to 82 years). The population was 76% White, 1% Black, 3% Hispanic, and 20% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease. Most (90%) patients reported ED of at least 1-year duration. In these 5 trials, CIALIS 5, 10, and 20 mg showed clinically meaningful and statistically significant improvements in all 3 primary efficacy variables (see Tables 2, 3, and 4). The treatment effect of CIALIS did not diminish over time.
### Table 2: Mean Endpoint and Change from Baseline for the EF Domain of the IIEF in the General ED Population in Five Primary Trials Outside the US

<table>
<thead>
<tr>
<th>Study</th>
<th>Endpoint [Change from baseline]</th>
<th>Placebo 15.0 [0.7]</th>
<th>CIALIS 5 mg 17.9 [4.0]</th>
<th>CIALIS 10 mg 20.0 [5.6]</th>
<th>CIALIS 20 mg 20.0 [5.6]</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>p=.006</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>14.4 [1.1]</td>
<td>17.5 [5.1]</td>
<td>20.6 [6.0]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=.002</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>18.1 [2.6]</td>
<td>22.6 [8.1]</td>
<td>25.0 [8.0]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p&lt;.001</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F*</td>
<td>12.7 [-1.6]</td>
<td></td>
<td>22.8 [6.8]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>p&lt;.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>14.5 [-0.9]</td>
<td>21.2 [6.6]</td>
<td>23.3 [8.0]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p&lt;.001</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Treatment duration in Study F was 6 months

### Table 3: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 2 ("Were you able to insert your penis into the partner's vagina?") in the General ED Population in Five Pivotal Trials Outside the US

<table>
<thead>
<tr>
<th>Study</th>
<th>Endpoint [Change from baseline]</th>
<th>Placebo 49% [6%]</th>
<th>CIALIS 5 mg 57% [15%]</th>
<th>CIALIS 10 mg 73% [29%]</th>
<th>CIALIS 20 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>p=.063</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>46% [2%]</td>
<td>56% [18%]</td>
<td>68% [15%]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=.008</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>55% [10%]</td>
<td>77% [35%]</td>
<td>85% [35%]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p&lt;.001</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F*</td>
<td>42% [-8%]</td>
<td></td>
<td>81% [27%]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>p&lt;.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>45% [-6%]</td>
<td>73% [21%]</td>
<td>76% [21%]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p&lt;.001</td>
<td>p&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Treatment duration in Study F was 6 months
Table 4: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 3 ("Did your erection last long enough for you to have successful intercourse?"") in the General ED Population in Five Pivotal Trials Outside the US

<table>
<thead>
<tr>
<th>Study</th>
<th>Endpoint [Change from baseline]</th>
<th>Placebo</th>
<th>CIALIS 5 mg</th>
<th>CIALIS 10 mg</th>
<th>CIALIS 20 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study C</td>
<td></td>
<td>26% [4%]</td>
<td>38% [19%]</td>
<td>58% [32%]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$p = .040$</td>
</tr>
<tr>
<td>Study D</td>
<td></td>
<td>28% [4%]</td>
<td>42% [24%]</td>
<td>51% [26%]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$p &lt; .001$</td>
</tr>
<tr>
<td>Study E</td>
<td></td>
<td>43% [15%]</td>
<td></td>
<td>70% [48%]</td>
<td>78% [50%]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$p &lt; .001$</td>
</tr>
<tr>
<td>Study F*</td>
<td></td>
<td>27% [1%]</td>
<td></td>
<td>74% [40%]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$p &lt; .001$</td>
</tr>
<tr>
<td>Study G</td>
<td></td>
<td>32% [5%]</td>
<td></td>
<td>57% [33%]</td>
<td>62% [29%]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$p &lt; .001$</td>
</tr>
</tbody>
</table>

* Treatment duration in Study F was 6 months

In addition, there were improvements in EF domain scores, success rates based upon SEP Questions 2 and 3, and patient-reported improvement in erections across patients with ED of all degrees of disease severity while taking CIALIS, compared to patients on placebo.

Therefore, in all 7 primary efficacy and safety studies, CIALIS showed statistically significant improvement in patients' ability to achieve an erection sufficient for vaginal penetration and to maintain the erection long enough for successful intercourse, as measured by the IIEF questionnaire and by SEP diaries.

**Efficacy in ED Patients with Diabetes Mellitus** — CIALIS was shown to be effective in treating ED in patients with diabetes mellitus. Patients with diabetes were included in all 7 primary efficacy studies in the general ED population (N=235) and in 1 study that specifically assessed CIALIS in ED patients with type 1 or type 2 diabetes (N=216). In this randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial, CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 5).
Table 5: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in ED Patients with Diabetes

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=71)</th>
<th>CIALIS 10 mg (N=73)</th>
<th>CIALIS 20 mg (N=72)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EF Domain Score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint (Change from baseline)</td>
<td>12.2 [0.1]</td>
<td>19.3 [6.4]</td>
<td>18.7 [7.3]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Insertion of Penis (SEP2)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint (Change from baseline)</td>
<td>30% [-4%]</td>
<td>57% [22%]</td>
<td>54% [23%]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Maintenance of Erection (SEP3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint (Change from baseline)</td>
<td>20% [2%]</td>
<td>48% [28%]</td>
<td>42% [29%]</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

**Efficacy in ED Patients following Radical Prostatectomy** — CIALIS was shown to be effective in treating patients who developed ED following bilateral nerve-sparing radical prostatectomy. In 1 randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial in this population (N=303), CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 6).

Table 6: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in Patients who Developed ED Following Bilateral Nerve-Sparing Radical Prostatectomy

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=102)</th>
<th>CIALIS 20 mg (N=201)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EF Domain Score</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint (Change from baseline)</td>
<td>13.3 [1.1]</td>
<td>17.7 [5.3]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Insertion of Penis (SEP2)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint (Change from baseline)</td>
<td>32% [2%]</td>
<td>54% [22%]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Maintenance of Erection (SEP3)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint (Change from baseline)</td>
<td>19% [4%]</td>
<td>41% [23%]</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

**Studies to Determine the Optimal Use of CIALIS** — Several studies were conducted with the objective of determining the optimal use of CIALIS in the treatment of ED. In 1 of these studies, the percentage of patients reporting successful erections within 30 minutes of dosing was determined. In this randomized, placebo-controlled, double-blinded trial, 223 patients were randomized to placebo, CIALIS 10, or 20 mg. Using a stopwatch, patients recorded the time following dosing at which a successful erection was obtained. A successful erection was defined as at least 1 erection in 4 attempts that led to successful intercourse. At 30 minutes, 35% (26/74), 38% (28/74), and 52% (39/75) of patients in the placebo, 10-, and 20-mg groups, respectively, reported successful erections as defined above.

Two studies were conducted to assess the efficacy of CIALIS at a given timepoint after dosing, specifically at 24 hours and at 36 hours after dosing.

In the first of these studies, 348 patients with ED were randomized to placebo or CIALIS 20 mg. Patients were encouraged to make 4 total attempts at intercourse; 2 attempts were to occur at 24 hours after dosing and 2 completely separate attempts were to occur at 36 hours after dosing. The results demonstrated a difference between the placebo group and the CIALIS group at each of the
pre-specified timepoints. At the 24-hour timepoint, (more specifically, 22 to 26 hours), 53/144 (37%) patients reported at least 1 successful intercourse in the placebo group versus 84/138 (61%) in the CIALIS 20-mg group. At the 36-hour timepoint (more specifically, 33 to 39 hours), 49/133 (37%) of patients reported at least 1 successful intercourse in the placebo group versus 88/137 (64%) in the CIALIS 20-mg group.

In the second of these studies, a total of 483 patients were evenly randomized to 1 of 6 groups: 3 different dosing groups (placebo, CIALIS 10, or 20 mg) that were instructed to attempt intercourse at 2 different times (24 and 36 hours post-dosing). Patients were encouraged to make 4 separate attempts at their assigned dose and assigned timepoint. In this study, the results demonstrated a statistically significant difference between the placebo group and the CIALIS groups at each of the pre-specified timepoints. At the 24-hour timepoint, the mean, per-patient percentage of attempts resulting in successful intercourse were 42, 56, and 67% for the placebo, CIALIS 10-, and 20-mg groups, respectively. At the 36-hour timepoint, the mean, per-patient percentage of attempts resulting in successful intercourse were 33, 56, and 62% for placebo, CIALIS 10-, and 20-mg groups, respectively.

INDICATIONS AND USAGE
CIALIS is indicated for the treatment of erectile dysfunction.

CONTRAINDICATIONS
Nitrates — Administration of CIALIS to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. In clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway (see Pharmacodynamics, Effects on Blood Pressure when CIALIS is Administered with Nitrates under CLINICAL PHARMACOLOGY).

Alpha Blockers — Administration of CIALIS to patients taking any alpha-adrenergic antagonist other than 0.4 mg once-daily tamsulosin is contraindicated. In a drug-drug interaction study, when tadalafil 20 mg was administered to healthy subjects taking doxazosin (8 mg daily), there was a significant augmentation of the blood-pressure-lowering effect of doxazosin (see Drug Interactions under PRECAUTIONS).

Hypersensitivity — CIALIS is contraindicated for patients with a known hypersensitivity to tadalafil or any component of the tablet.

WARNINGS
Cardiovascular
General — Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Therefore, treatments for erectile dysfunction, including CIALIS, should not be used in men for whom sexual activity is inadvisable as a result of their underlying cardiovascular status.

Left Ventricular Outflow Obstruction — Patients with left ventricular outflow obstruction, (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators, including PDE5 inhibitors.

Patients Not Studied in Clinical Trials
The following groups of patients with cardiovascular disease were not included in clinical safety and efficacy trials for CIALIS, and, therefore, the use of CIALIS is not recommended in these groups until further information is available:

- patients with a myocardial infarction within the last 90 days
- patients with unstable angina or angina occurring during sexual intercourse
- patients with New York Heart Association Class 2 or greater heart failure in the last 6 months
- patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled
  hypertension (>170/100 mm Hg)
- patients with a stroke within the last 6 months

In addition, patients with known hereditary degenerative retinal disorders, including retinitis
pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.

**Prolonged Erection**

There have been rare reports of prolonged erections greater than 4 hours and priapism (painful
erections greater than 6 hours in duration) for this class of compounds. Priapism, if not treated
promptly, can result in irreversible damage to the erectile tissue. Patients who have an erection lasting
greater than 4 hours, whether painful or not, should seek emergency medical attention.

**PRECAUTIONS**

Evaluation of erectile dysfunction should include an appropriate medical assessment to identify
potential underlying causes, as well as treatment options.

Before prescribing CIALIS, it is important to note the following:

**Renal Insufficiency**

CIALIS should be limited to 5 mg not more than once daily in patients with severe renal
insufficiency or end-stage renal disease. The starting dose of CIALIS in patients with a moderate
degree of renal insufficiency should be 5 mg not more than once daily, and the maximum dose should
be limited to 10 mg not more than once in every 48 hours. No dose adjustment is required in patients
with mild renal insufficiency (see Pharmacokinetics in Special Populations under CLINICAL
PHARMACOLOGY).

**Hepatic Impairment**

In patients with mild or moderate hepatic impairment, the dose of CIALIS should not exceed 10 mg.
Because of insufficient information in patients with severe hepatic impairment, use of CIALIS in this
group is not recommended (see Pharmacokinetics in Special Populations under CLINICAL
PHARMACOLOGY).

**Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4)**

CIALIS is metabolized predominantly by CYP3A4 in the liver. The dose of CIALIS should be
limited to 10 mg no more than once every 72 hours in patients taking potent inhibitors of CYP3A4
such as ritonavir, ketoconazole, and itraconazole (see Effects of Other Drugs on CIALIS under Drug
Interactions).

**General**

As with other PDE5 inhibitors, tadalafil has mild systemic vasodilatory properties that may result in
transient decreases in blood pressure. In a clinical pharmacology study, tadalafil 20 mg resulted in a
mean maximal decrease in supine blood pressure, relative to placebo, of 1.6/0.8 mm Hg in healthy
subjects (see Clinical Studies under CLINICAL PHARMACOLOGY). While this effect should not be
of consequence in most patients, prior to prescribing CIALIS, physicians should carefully consider
whether their patients with underlying cardiovascular disease could be affected adversely by such
vasodilatory effects. Patients with significant left ventricular outflow obstruction or severely impaired
autonomic control of blood pressure may be particularly sensitive to the actions of vasodilators.
The safety and efficacy of combinations of CIALIS and other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.

CIALIS should be used with caution in patients who have conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease).

When administered in combination with aspirin, tadalafil 20 mg did not prolong bleeding time, relative to aspirin alone. CIALIS has not been administered to patients with bleeding disorders or significant active peptic ulceration. Although CIALIS has not been shown to increase bleeding times in healthy subjects, use in patients with bleeding disorders or significant active peptic ulceration should be based upon a careful risk-benefit assessment and caution.

Information for Patients

Physicians should discuss with patients the contraindication of CIALIS with regular and/or intermittent use of organic nitrates. Patients should be counseled that concomitant use of CIALIS with nitrates could cause blood pressure to suddenly drop to an unsafe level, resulting in dizziness, syncope, or even heart attack or stroke.

Physicians should discuss with patients the appropriate action in the event that they experience anginal chest pain requiring nitroglycerin following intake of CIALIS. In such a patient, who has taken CIALIS, where nitrate administration is deemed medically necessary for a life-threatening situation, at least 48 hours should have elapsed after the last dose of CIALIS before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring. Therefore, patients who experience anginal chest pain after taking CIALIS should seek immediate medical attention.

Physicians should inform their patients that concomitant use of CIALIS with alpha-adrenergic antagonists (other than 0.4 mg once-daily tamsulosin) is contraindicated because coadministration can lead to significant reductions in blood pressure.

Physicians should discuss with patients the potential for CIALIS to augment the blood-pressure-lowering effect of other anti-hypertensive medications.

Patients should be made aware that both alcohol and CIALIS, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Therefore, physicians should inform patients that substantial consumption of alcohol (e.g., 5 units or greater) in combination with CIALIS can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.

Physicians should consider the potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Patients who experience symptoms upon initiation of sexual activity should be advised to refrain from further sexual activity and seek immediate medical attention.

There have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Patients who have an erection lasting greater than 4 hours, whether painful or not, should seek emergency medical attention.

The use of CIALIS offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV) should be considered.

Patients should read the patient leaflet entitled “INFORMATION FOR THE PATIENT” before starting therapy with CIALIS and each time the prescription is renewed or refilled.
Drug Interactions

Effects of Other Drugs on CIALIS

Cytochrome P450 Inhibitors

CIALIS is a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Ketoconazole — Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20-mg single-dose exposure (AUC) by 312% and $C_{\text{max}}$ by 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and $C_{\text{max}}$ by 15%, relative to the values for tadalafil 10 mg alone.

HIV Protease inhibitor — Ritonavir (200 mg twice daily), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 124% with no change in $C_{\text{max}}$, relative to the values for tadalafil 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure (see DOSAGE AND ADMINISTRATION).

Based upon these results, in patients taking concomitant potent CYP3A4 inhibitors, the dose of CIALIS should not exceed 10 mg, and CIALIS should not be taken more frequently than once in every 72 hours (see DOSAGE AND ADMINISTRATION).

Other cytochrome P450 inhibitors — Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.

Cytochrome P450 Inducers

Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure.

Rifampin — Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and $C_{\text{max}}$ by 46%, relative to the values for tadalafil 10 mg alone. Although specific interactions have not been studied, other CYP3A4 inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure. No dose adjustment is warranted.

Gastrointestinal Drugs

H2 antagonists — An increase in gastric pH resulting from administration of nizatidine had no significant effect on tadalafil pharmacokinetics.

Antacids — Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering exposure (AUC) to tadalafil.

Effects of CIALIS on Other Drugs

Drugs Metabolized by Cytochrome P450

CIALIS is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.

CYP1A2 substrate — Tadalafil had no clinically significant effect on the pharmacokinetics of theophylline. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed.

CYP3A4 substrates — Tadalafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin.

CYP2C9 substrate — Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin.
Alcohol

Alcohol and PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. The interaction of tadalafil with alcohol was evaluated in 3 clinical pharmacology studies. In 2 of these, alcohol was administered at a dose of 0.7 g/kg, which is equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male, and tadalafil was administered at a dose of 10 mg in 1 study and 20 mg in another. In both these studies, all patients imbibed the entire alcohol dose within 10 minutes of starting. In one of these two studies, blood alcohol levels of 0.08% were confirmed. In these two studies, more patients had clinically significant decreases in blood pressure on the combination of tadalafil and alcohol as compared to alcohol alone. Some subjects reported postural dizziness, and orthostatic hypotension was observed in some subjects. When tadalafil 20 mg was administered with a lower dose of alcohol (0.6 g/kg, which is equivalent to approximately 4 ounces of 80-proof vodka, administered in less than 10 minutes), orthostatic hypotension was not observed, dizziness occurred with similar frequency to alcohol alone, and the hypotensive effects of alcohol were not potentiated.

Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations.

Both alcohol and CIALIS, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with CIALIS can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.

Anti-Hypertensives

PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood-pressure-lowering effects of selected anti-hypertensive medications.

Alpha Blockers

Doxazosin — When tadalafil 20 mg was administered to healthy subjects taking doxazosin (8 mg daily), an alpha[1]-adrenergic blocker, there was significant augmentation of the blood-pressure-lowering effect of doxazosin.

Tamsulosin — In a clinical pharmacology study, when a single dose of tadalafil 20 mg was administered to healthy subjects taking 0.4 mg once-daily tamsulosin, a selective alpha[1A]-adrenergic blocker, no significant decreases in blood pressure were observed.

Therefore, based upon significant augmentation of the blood-pressure-lowering effect of doxazosin, an alpha[1]-adrenergic blocker, and no significant effect seen with 0.4 mg once-daily tamsulosin, a selective alpha[1A]-adrenergic blocker, administration of CIALIS to patients taking any alpha-adrenergic blocker other than 0.4 mg once-daily tamsulosin is contraindicated.

Other Anti-Hypertensive Agents

Amlodipine — A study was conducted to assess the interaction of amlodipine (5 mg daily) and tadalafil 10 mg. There was no effect of tadalafil on amlodipine blood levels and no effect of amlodipine on tadalafil blood levels. The mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10 mg in subjects taking amlodipine was 3/2 mm Hg, compared to placebo. In a similar study using tadalafil 20 mg, there were no clinically significant differences between tadalafil and placebo in subjects taking amlodipine.

Metoprolol — A study was conducted to assess the interaction of sustained-release metoprolol (25 to 200 mg daily) and tadalafil 10 mg. Following dosing, the mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10 mg in subjects taking metoprolol was 5/3 mm Hg, compared to placebo.

Bendrofluazide — A study was conducted to assess the interaction of bendrofluazide (2.5 mg daily) and tadalafil 10 mg. Following dosing, the mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10 mg in subjects taking bendrofluazide was 6/4 mm Hg, compared to placebo.
Enalapril — A study was conducted to assess the interaction of enalapril (10 to 20 mg daily) and tadalafil 10 mg. Following dosing, the mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10 mg in subjects taking enalapril was 4/1 mm Hg, compared to placebo.

Angiotensin II receptor blocker (and other anti-hypertensives) — A study was conducted to assess the interaction of angiotensin II receptor blockers and tadalafil 20 mg. Subjects in the study were taking any marketed angiotensin II receptor blocker, either alone, as a component of a combination product, or as part of a multiple anti-hypertensive regimen. Following dosing, ambulatory measurements of blood pressure revealed differences between tadalafil and placebo of 8/4 mm Hg in systolic/diastolic blood pressure.

Aspirin
Tadalafil did not potentiate the increase in bleeding time caused by aspirin.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 10-fold for mice, and 14- and 26-fold for male and female rats, respectively, the exposures in human males given Maximum Recommended Human Dose (MRHD) of 20 mg.

Tadalafil was not mutagenic in the in vitro bacterial Ames assays or the forward mutation test in mouse lymphoma cells. Tadalafil was not clastogenic in the in vitro chromosomal aberration test in human lymphocytes or the in vivo rat micronucleus assays.

There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 14-fold for males or 26-fold for females the exposures observed in human males given the MRHD of 20 mg. In beagle dogs given tadalafil daily for 3 to 12 months, there was treatment-related non-reversible degeneration and atrophy of the seminiferous tubular epithelium in the testes in 20-100% of the dogs that resulted in a decrease in spermatogenesis in 40-75% of the dogs at doses of ≥10 mg/kg/day. Systemic exposure (based on AUC) at no-observed-adverse-effect-level (NOAEL) (10 mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 20 mg.

There were no treatment-related testicular findings in rats or mice treated with doses up to 400 mg/kg/day for 2 years.

In men, there were no clinically relevant effects on sperm concentration, sperm count, motility, or morphology in placebo-controlled studies of daily doses of tadalafil 10 mg (N=204) or 20 mg (N=217) for 6 months. In addition, tadalafil had no effect on serum levels of testosterone, luteinizing hormone, or follicle stimulating hormone in males.

Animal Toxicology
Animal studies showed vascular inflammation in tadalafil-treated mice, rats, and dogs. In mice and rats, lymphoid necrosis and hemorrhage were seen in the spleen, thymus, and mesenteric lymph nodes at unbound tadalafil exposure of 2- to 33-fold above the human exposure (AUCs) at the MRHD of 20 mg. In dogs, an increased incidence of disseminated arteritis was observed in 1- and 6-month studies at unbound tadalafil exposure of 1- to 54-fold above the human exposure (AUC) at the MRHD of 20 mg. In a 12-month dog study, no disseminated arteritis was observed, but 2 dogs exhibited marked decreases in white blood cells (neutrophils) and moderate decreases in platelets with inflammatory signs at unbound tadalafil exposures of approximately 14- to 18-fold the human exposure at the MRHD of 20 mg. The abnormal blood-cell findings were reversible within 2 weeks upon removal of the drug.
Pregnancy, Nursing Mothers, and Pediatric Use

CIALIS is not indicated for use in newborns, children, or women.

Tadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats. Tadalafil and/or its metabolites were secreted into the milk in lactating rats at concentrations approximately 2.4-fold greater than found in the plasma. Following a single-oral dose of 10 mg/kg, approximately 0.1% of the total radioactive dose was excreted into the milk within 3 hours. It is not known if tadalafil and/or its metabolites is excreted in human breast milk. Use of tadalafil in nursing mothers is not recommended.

Pregnancy Category B — There was no evidence of teratogenicity, embryotoxicity, or fetotoxicity in rat or mouse fetuses that received up to 1000 mg/kg/day during the major organ development. Plasma exposure at this dose is approximately 11-fold greater than the AUC values for unbound tadalafil in humans given the MRHD of 20 mg. In a rat prenatal and postnatal development study at doses of 60, 200, and 1000 mg/kg, there was a reduction in postnatal survival of pups. The no-observed-effect-level (NOEL) for maternal toxicity was 200 mg/kg/day and for developmental toxicity was 30 mg/kg/day, which gives approximately 16- and 10-fold exposure multiples, respectively, of the human AUC for the MRHD dose of 20 mg. There are no adequate and well-controlled studies of tadalafil in pregnant women.

Geriatric Use

Approximately 25% of patients in the primary efficacy and safety studies of tadalafil were greater than 65 years of age. No overall differences in efficacy and safety were observed between older and younger patients. No dose adjustment is warranted based on age alone. However, greater sensitivity to medications in some older individuals should be considered (see Special Populations under CLINICAL PHARMACOLOGY).

ADVERSE REACTIONS

Tadalafil was administered to over 5700 men (mean age 59, range 19 to 87 years) during clinical trials worldwide. Over 1000 patients were treated for 1 year or longer and over 1300 patients were treated for 6 months or more.

In placebo-controlled Phase 3 clinical trials, the discontinuation rate due to adverse events in patients treated with tadalafil 10 or 20 mg was 3.1%, compared to 1.4% in placebo-treated patients.

When tadalafil was taken as recommended in the placebo-controlled clinical trials, the following adverse events were reported (see Table 7):

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Placebo (N=476)</th>
<th>Tadalafil 5 mg (N=151)</th>
<th>Tadalafil 10 mg (N=394)</th>
<th>Tadalafil 20 mg (N=635)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>5%</td>
<td>11%</td>
<td>11%</td>
<td>15%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>1%</td>
<td>4%</td>
<td>8%</td>
<td>10%</td>
</tr>
<tr>
<td>Back pain</td>
<td>3%</td>
<td>3%</td>
<td>5%</td>
<td>6%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>1%</td>
<td>1%</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>1%</td>
<td>2%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Flushing*</td>
<td>1%</td>
<td>2%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Pain in limb</td>
<td>1%</td>
<td>1%</td>
<td>3%</td>
<td>3%</td>
</tr>
</tbody>
</table>

* The term flushing includes: facial flushing and flushing
Back pain or myalgia was reported at incidence rates described in Table 7. In tadalafl clinical pharmacology trials, back pain or myalgia generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours. The back pain/myalgia associated with tadalafl treatment was characterized by diffuse bilateral lower lumbar, gluteal, thigh, or thoracolumbar muscular discomfort and was exacerbated by recumbancy. In general, pain was reported as mild or moderate in severity and resolved without medical treatment, but severe back pain was reported infrequently (<5% of all reports). When medical treatment was necessary, acetaminophen or non-steroidal anti-inflammatory drugs were generally effective; however, in a small percentage of subjects who required treatment, a mild narcotic (e.g. codeine) was used. Overall, approximately 0.5% of all tadalafl-treated subjects discontinued treatment as a consequence of back pain/myalgia. Diagnostic testing, including measures for inflammation, muscle injury, or renal damage revealed no evidence of medically significant underlying pathology.

Across all studies with any tadalafl dose, reports of changes in color vision were rare (<0.1% of patients).

The following section identifies additional, less frequent events (<2%) reported in controlled clinical trials; a causal relationship of these events to CIALIS is uncertain. Excluded from this list are those events that were minor, those with no plausible relation to drug use, and reports too imprecise to be meaningful:

- **Body as a whole**: asthenia, face edema, fatigue, pain
- **Cardiovascular**: angina pectoris, chest pain, hypotension, hypertension, myocardial infarction, postural hypotension, palpitations, syncope, tachycardia
- **Digestive**: abnormal liver function tests, diarrhea, dry mouth, dysphagia, esophagitis, gastroesophageal reflux, gastritis, GGTP increased, loose stools, nausea, upper abdominal pain, vomiting
- **Musculoskeletal**: arthralgia, neck pain
- **Nervous**: dizziness, hypesthesia, insomnia, paresthesia, somnolence, vertigo
- **Respiratory**: dyspnea, epistaxis, pharyngitis
- **Skin and Appendages**: pruritus, rash, sweating
- **Ophthalmologic**: blurred vision, changes in color vision, conjunctivitis (including conjunctival hyperemia), eye pain, lacrimation increase, swelling of eyelids
- **Urogenital**: erection increased, spontaneous penile erection

**OVERDOSE**

Single doses up to 500 mg have been given to healthy subjects, and multiple daily doses up to 100 mg have been given to patients. Adverse events were similar to those seen at lower doses. In cases of overdose, standard supportive measures should be adopted as required. Hemodialysis contributes negligibly to tadalafl elimination.

**DOSAGE AND ADMINISTRATION**

The recommended starting dose of CIALIS in most patients is 10 mg, taken prior to anticipated sexual activity. The dose may be increased to 20 mg or decreased to 5 mg, based on individual efficacy and tolerability. The maximum recommended dosing frequency is once per day in most patients.

CIALIS was shown to improve erectile function compared to placebo up to 36 hours following dosing. Therefore, when advising patients on optimal use of CIALIS, this should be taken into consideration.

CIALIS may be taken without regard to food.

**Renal Insufficiency** — No dose adjustment is required in patients with mild renal insufficiency. For patients with moderate (creatinine clearance 31 to 50 mL/min) renal insufficiency, a starting dose of
5 mg not more than once daily is recommended, and the maximum dose should be limited to 10 mg not more than once in every 48 hours. For patients with severe (creatinine clearance <30 mL/min) renal insufficiency on hemodialysis, the maximum recommended dose is 5 mg (see General and Patients with Renal Insufficiency under PRECAUTIONS and Pharmacokinetics in Special Populations under CLINICAL PHARMACOLOGY).

**Hepatic Impairment** — For patients with mild or moderate degrees of hepatic impairment (Child-Pugh Class A or B), the dose of CIALIS should not exceed 10 mg once daily. In patients with severe hepatic impairment (Child-Pugh Class C), the use of CIALIS is not recommended (see Patients with Hepatic Impairment under PRECAUTIONS and Pharmacokinetics in Special Populations under CLINICAL PHARMACOLOGY).

**Concomitant Medications** — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of CIALIS is 10 mg, not to exceed once every 72 hours (see General and Drug Interactions under PRECAUTIONS).

Concomitant use of nitrates in any form and alpha-adrenergic blockers (other than 0.4 mg once-daily tamsulosin) is contraindicated (see CONTRAINDICATIONS and Drug Interactions under PRECAUTIONS).

**Geriatrics** — No dose adjustment is required in patients >65 years of age.

**HOW SUPPLIED**

CIALIS® (tadalafil) is supplied as follows:

Three strengths of film-coated, almond-shaped tablets are available in different sizes and different shades of yellow, and supplied in the following package sizes:

- 5-mg tablets debossed with “C 5”
  - Bottles of 30 NDC 0002-4462-30
- 10-mg tablets debossed with “C 10”
  - Bottles of 30 NDC 0002-4463-30
- 20-mg tablets debossed with “C 20”
  - Bottles of 30 NDC 0002-4464-30

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Keep out of reach of children.

Literature issued November, 2003

**Manufactured for Lilly ICOS LLC**
by Eli Lilly and Company
Indianapolis, IN 46285, USA

NL 3534 AMP PRINTED IN USA

Copyright © 2003, Lilly ICOS LLC. All rights reserved.
Patient Information

CIALIS® (See-AL-iss)
(tadalafil)
tablets

Read the Patient Information about CIALIS before you start taking it and again each time you get a refill. There may be new information. You may also find it helpful to share this information with your partner. This leaflet does not take the place of talking with your doctor. You and your doctor should talk about CIALIS when you start taking it and at regular checkups. If you do not understand the information, or have questions, talk with your doctor or pharmacist.

What important information should you know about CIALIS?

CIALIS can cause your blood pressure to drop suddenly to an unsafe level if it is taken with certain other medicines. You could get dizzy, faint, or have a heart attack or stroke.

Do not take CIALIS if you:

- take any medicines called “nitrates.”
- use recreational drugs called “poppers” like amyl nitrate and butyl nitrate.
- take medicines called alpha blockers, other than Flomax® (tamsulosin HCl) 0.4 mg daily.

(See “Who should not take CIALIS?”)

Tell all your healthcare providers that you take CIALIS. If you need emergency medical care for a heart problem, it will be important for your healthcare provider to know when you last took CIALIS.

After taking a single tablet, some of the active ingredient of CIALIS remains in your body for more than 2 days. The active ingredient can remain longer if you have problems with your kidneys or liver, or you are taking certain other medications (see “Can other medications affect CIALIS?”).

What is CIALIS?

CIALIS is a prescription medicine taken by mouth for the treatment of erectile dysfunction (ED) in men.

ED is a condition where the penis does not harden and expand when a man is sexually excited, or when he cannot keep an erection. A man who has trouble getting or keeping an erection should see his doctor for help if the condition bothers him. CIALIS may help a man with ED get and keep an erection when he is sexually excited.

CIALIS does not:

- cure ED
- increase a man’s sexual desire
- protect a man or his partner from sexually transmitted diseases, including HIV. Speak to your doctor about ways to guard against sexually transmitted diseases.
- serve as a male form of birth control
CIALIS is only for men with ED. CIALIS is not for women or children. CIALIS must be used only under a doctor’s care.

How does CIALIS work?
When a man is sexually stimulated, his body's normal physical response is to increase blood flow to his penis. This results in an erection. CIALIS helps increase blood flow to the penis and may help men with ED get and keep an erection satisfactory for sexual activity. Once a man has completed sexual activity, blood flow to his penis decreases, and his erection goes away.

Who can take CIALIS?
Talk to your doctor to decide if CIALIS is right for you.

CIALIS has been shown to be effective in men over the age of 18 years who have erectile dysfunction, including men with diabetes or who have undergone prostatectomy.

Who should not take CIALIS?
Do not take CIALIS if you:

- take any medicines called "nitrates" (See "What important information should you know about CIALIS?"). Nitrates are commonly used to treat angina. Angina is a symptom of heart disease and can cause pain in your chest, jaw, or down your arm.
  
Medicines called nitrates include nitroglycerin that is found in tablets, sprays, ointments, pastes, or patches. Nitrates can also be found in other medicines such as isosorbide dinitrate or isosorbide mononitrate. Some recreational drugs called "poppers" also contain nitrates, such as amyl nitrate and butyl nitrate. Do not use CIALIS if you are using these drugs. Ask your doctor or pharmacist if you are not sure if any of your medicines are nitrates.

- take medicines called "alpha blockers", other than Flomax® 0.4 mg daily. Alpha blockers are sometimes prescribed for prostate problems or high blood pressure. If CIALIS is taken with alpha blockers other than Flomax® 0.4 mg daily, your blood pressure could suddenly drop to an unsafe level. You could get dizzy and faint.

- you have been told by your healthcare provider to not have sexual activity because of health problems. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease.

- are allergic to CIALIS or any of its ingredients. The active ingredient in CIALIS is called tadalafil. See the end of this leaflet for a complete list of ingredients.

What should you discuss with your doctor before taking CIALIS?
Before taking CIALIS, tell your doctor about all your medical problems, including if you:

- have heart problems such as angina, heart failure, irregular heartbeats, or have had a heart attack. Ask your doctor if it is safe for you to have sexual activity.

- have low blood pressure or have high blood pressure that is not controlled

- have had a stroke

- have liver problems

- have kidney problems or require dialysis

- have retinitis pigmentosa, a rare genetic (runs in families) eye disease

- have stomach ulcers
• have a bleeding problem
• have a deformed penis shape or Peyronie’s disease
• have had an erection that lasted more than 4 hours
• have blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia

Can other medications affect CIALIS?

Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. CIALIS and other medicines may affect each other. Always check with your doctor before starting or stopping any medicines. Especially tell your doctor if you take any of the following:

• medicines called nitrates (See “What important information should you know about CIALIS?”)
• medicines called alpha blockers. These include Hytrin® (terazosin), Flomax® (tamsulosin), Cardura® (doxazosin), Minipress® (prazosin) or Uroxatral® (alfuzosin).
• ritonavir (Norvir®) or indinavir (Crixivan®)
• ketoconazole or itraconazole (such as Nizoral® or Sporanox®)
• erythromycin
• other medicines or treatments for ED

How should you take CIALIS?

Take CIALIS exactly as your doctor prescribes. CIALIS comes in different doses (5 mg, 10 mg, and 20 mg). For most men, the recommended starting dose is 10 mg. CIALIS should be taken no more than once a day. Some men can only take a low dose of CIALIS because of medical conditions or medicines they take. Your doctor will prescribe the dose that is right for you.

• If you have kidney problems, your doctor may start you on a lower dose of CIALIS.
• If you have kidney or liver problems or you are taking certain medications, your doctor may limit your highest dose of CIALIS to 10 mg and may also limit you to one tablet in 48 hours (2 days) or one tablet in 72 hours (3 days).

Take one CIALIS tablet before sexual activity. In some patients, the ability to have sexual activity was improved at 30 minutes after taking CIALIS when compared to a sugar pill. The ability to have sexual activity was improved up to 36 hours after taking CIALIS when compared to a sugar pill. You and your doctor should consider this in deciding when you should take CIALIS prior to sexual activity. Some form of sexual stimulation is needed for an erection to happen with CIALIS. CIALIS may be taken with or without meals.

Do not change your dose of CIALIS without talking to your doctor. Your doctor may lower your dose or raise your dose, depending on how your body reacts to CIALIS.

Do not drink alcohol to excess when taking CIALIS (for example, 5 glasses of wine or 5 shots of whiskey). When taken in excess, alcohol can increase your chances of getting a headache or getting dizzy, increasing your heart rate, or lowering your blood pressure.

If you take too much CIALIS, call your doctor or emergency room right away.

What are the possible side effects of CIALIS?

The most common side effects with CIALIS are headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects usually go away after a few hours. Patients who
get back pain and muscle aches usually get it 12 to 24 hours after taking CIALIS. Back pain and muscle aches usually go away by themselves within 48 hours. Call your doctor if you get a side effect that bothers you or one that will not go away.

**CIALIS may uncommonly cause:**

- **an erection that won’t go away (priapism).** If you get an erection that lasts more than 4 hours, get medical help right away. Priapism must be treated as soon as possible or lasting damage can happen to your penis including the inability to have erections.
- **vision changes**, such as seeing a blue tinge to objects or having difficulty telling the difference between the colors blue and green.

These are not all the side effects of CIALIS. For more information, ask your doctor or pharmacist.

**How should CIALIS be stored?**

- Store CIALIS at room temperature between 59° and 86°F (15° and 30°C).
- Keep CIALIS and all medicines out of the reach of children.

**General Information about CIALIS:**

Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use CIALIS for a condition for which it was not prescribed. Do not give CIALIS to other people, even if they have the same symptoms that you have. It may harm them.

This leaflet summarizes the most important information about CIALIS. If you would like more information, talk with your healthcare provider. You can ask your doctor or pharmacist for information about CIALIS that is written for health professionals.

For more information you can also visit [www.cialis.com](http://www.cialis.com), or call 1-877-242-5441.

**What are the ingredients of CIALIS?**

**Active Ingredient:** tadalafil

**Inactive Ingredients:** croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.

**Rx only**

Norvir® (ritonavir) and Hytrin® (terazosin) are registered trademarks of Abbott Laboratories

Crixivan® (indinavir sulfate) is a registered trademark of Merck & Co., Inc.

Nizoral® (ketoconazole) and Sporanox® (itraconazole) are registered trademarks of Janssen Pharmaceutica, Inc.

Flomax® (tamsulosin) is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc.

Cardura® (doxazosin) and Minipress® (prazosin) are registered trademarks of Pfizer, Inc.

Uroxatral® (alfuzosin) is a registered trademark of Sanofi-Synthelabo

Literature issued November, 2003
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-------------------
Florence Houn
11/21/03 10:33:13 AM